There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments.
Establishment Labs Holdings (ESTA)
In a report released yesterday, Anthony Petrone from Mizuho Securities reiterated a Buy rating on Establishment Labs Holdings, with a price target of $65.00. The company’s shares closed last Thursday at $56.83.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
Establishment Labs Holdings has an analyst consensus of Strong Buy, with a price target consensus of $60.00, a 10.3% upside from current levels. In a report issued on May 2, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.
See today’s best-performing stocks on TipRanks >>
Cytokinetics (CYTK)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics on May 8 and set a price target of $99.00. The company’s shares closed last Thursday at $64.02.
According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $97.58 average price target, representing a 43.1% upside. In a report issued on May 8, Goldman Sachs also maintained a Buy rating on the stock with a $85.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ESTA:
- Establishment Labs reports Q1 EPS (58c), consensus (67c)
- Establishment Labs price target raised to $62 from $53 at BTIG
- Establishment Labs price target raised to $60 from $49 at Citi
- Establishment Labs says FDA schedules preapproval inspection for Motiva facility
- Establishment Labs participates in a conference call with JPMorgan
